China Resources Pharmaceutical: China Resources Pharmaceutical Investment plans to publicly list and sell approximately 5.88% equity stake in Tianmai Biotechnology.

China Resources Pharmaceutical announced that its wholly-owned subsidiary, China Resources Pharmaceutical Investment, has initiated a potential sale of approximately 5.88% of the shares held in Tianmai Biotech. The transaction will be conducted through the Shanghai United Property Exchange with a preliminary listing price of about RMB 510 million. Currently, China Resources Pharmaceutical Investment and its subsidiaries hold approximately 23.75% of the shares in Tianmai Biotech. The potential sale is independent and unrelated to certain equity interests in Tianmai Biotech previously sold by China Resources Pharmaceutical Investment and its subsidiaries.